Trial · NCT00760474
Results by group188
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 188
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Glutamine/Creatine (Gln/Cr) and Glutamate/Creatine (Glu/Cr) Ratios Measured by Proton Magnetic Resonance Spectroscopy (1H-MRS) | Pregabalin | Glu/Cr ratio posterior insula - pre-dose | 1.1751 | Standard Deviation 0.119537 | ratio |
| Glutamine/Creatine (Gln/Cr) and Glutamate/Creatine (Glu/Cr) Ratios Measured by Proton Magnetic Resonance Spectroscopy (1H-MRS) | Placebo | Glu/Cr ratio posterior insula - pre-dose | 1.13253 | Standard Deviation 0.123897 | ratio |
| Glutamine/Creatine (Gln/Cr) and Glutamate/Creatine (Glu/Cr) Ratios Measured by Proton Magnetic Resonance Spectroscopy (1H-MRS) | Pregabalin | Glu/Cr ratio posterior insula - post-dose | 1.1046 | Standard Deviation 0.14180 | ratio |
| Glutamine/Creatine (Gln/Cr) and Glutamate/Creatine (Glu/Cr) Ratios Measured by Proton Magnetic Resonance Spectroscopy (1H-MRS) | Placebo | Glu/Cr ratio posterior insula - post-dose | 1.17129 | Standard Deviation 0.151535 | ratio |
| Glutamine/Creatine (Gln/Cr) and Glutamate/Creatine (Glu/Cr) Ratios Measured by Proton Magnetic Resonance Spectroscopy (1H-MRS) | Pregabalin | Gln/Cr ratio posterior insula - pre-dose | 0.5311 | Standard Deviation 0.117359 | ratio |
| Glutamine/Creatine (Gln/Cr) and Glutamate/Creatine (Glu/Cr) Ratios Measured by Proton Magnetic Resonance Spectroscopy (1H-MRS) | Placebo | Gln/Cr ratio posterior insula - pre-dose | 0.52635 | Standard Deviation 0.143649 | ratio |
| Glutamine/Creatine (Gln/Cr) and Glutamate/Creatine (Glu/Cr) Ratios Measured by Proton Magnetic Resonance Spectroscopy (1H-MRS) | Pregabalin | Gln/Cr ratio posterior insula - post-dose | 0.4857 | Standard Deviation 0.14534 | ratio |
| Glutamine/Creatine (Gln/Cr) and Glutamate/Creatine (Glu/Cr) Ratios Measured by Proton Magnetic Resonance Spectroscopy (1H-MRS) | Placebo | Gln/Cr ratio posterior insula - post-dose | 0.51553 | Standard Deviation 0.147882 | ratio |
| Glutamine/Creatine (Gln/Cr) and Glutamate/Creatine (Glu/Cr) Ratios Measured by Proton Magnetic Resonance Spectroscopy (1H-MRS) | Pregabalin | Glx/Cr ratio posterior insula - pre-dose | 1.70624 | Standard Deviation 0.177312 | ratio |
| Glutamine/Creatine (Gln/Cr) and Glutamate/Creatine (Glu/Cr) Ratios Measured by Proton Magnetic Resonance Spectroscopy (1H-MRS) | Placebo | Glx/Cr ratio posterior insula - pre-dose | 1.65894 | Standard Deviation 0.215505 | ratio |
| Glutamine/Creatine (Gln/Cr) and Glutamate/Creatine (Glu/Cr) Ratios Measured by Proton Magnetic Resonance Spectroscopy (1H-MRS) | Pregabalin | Glx/Cr ratio posterior insula - post-dose | 1.5903 | Standard Deviation 0.19461 | ratio |
| Glutamine/Creatine (Gln/Cr) and Glutamate/Creatine (Glu/Cr) Ratios Measured by Proton Magnetic Resonance Spectroscopy (1H-MRS) | Placebo | Glx/Cr ratio posterior insula - post-dose | 1.68747 | Standard Deviation 0.227398 | ratio |
| Glutamine/Creatine (Gln/Cr) and Glutamate/Creatine (Glu/Cr) Ratios Measured by Proton Magnetic Resonance Spectroscopy (1H-MRS) | Pregabalin | Glu/Cr ratio anterior insula - pre-dose | 1.22731 | Standard Deviation 0.154333 | ratio |
| Glutamine/Creatine (Gln/Cr) and Glutamate/Creatine (Glu/Cr) Ratios Measured by Proton Magnetic Resonance Spectroscopy (1H-MRS) | Placebo | Glu/Cr ratio anterior insula - pre-dose | 1.23788 | Standard Deviation 0.183282 | ratio |
| Glutamine/Creatine (Gln/Cr) and Glutamate/Creatine (Glu/Cr) Ratios Measured by Proton Magnetic Resonance Spectroscopy (1H-MRS) | Pregabalin | Glu/Cr ratio anterior insula - post-dose | 1.2393 | Standard Deviation 0.22290 | ratio |
| Glutamine/Creatine (Gln/Cr) and Glutamate/Creatine (Glu/Cr) Ratios Measured by Proton Magnetic Resonance Spectroscopy (1H-MRS) | Placebo | Glu/Cr ratio anterior insula - post-dose | 1.18524 | Standard Deviation 0.164847 | ratio |
| Glutamine/Creatine (Gln/Cr) and Glutamate/Creatine (Glu/Cr) Ratios Measured by Proton Magnetic Resonance Spectroscopy (1H-MRS) | Pregabalin | Gln/Cr ratio anterior insula - pre-dose | 0.53144 | Standard Deviation 0.115606 | ratio |
| Glutamine/Creatine (Gln/Cr) and Glutamate/Creatine (Glu/Cr) Ratios Measured by Proton Magnetic Resonance Spectroscopy (1H-MRS) | Placebo | Gln/Cr ratio anterior insula - pre-dose | 0.47882 | Standard Deviation 0.143684 | ratio |
| Glutamine/Creatine (Gln/Cr) and Glutamate/Creatine (Glu/Cr) Ratios Measured by Proton Magnetic Resonance Spectroscopy (1H-MRS) | Pregabalin | Gln/Cr ratio anterior insula - post-dose | 0.5290 | Standard Deviation 0.19367 | ratio |
| Glutamine/Creatine (Gln/Cr) and Glutamate/Creatine (Glu/Cr) Ratios Measured by Proton Magnetic Resonance Spectroscopy (1H-MRS) | Placebo | Gln/Cr ratio anterior insula - post-dose | 0.47541 | Standard Deviation 0.100247 | ratio |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00760474/results